Introduction
In 2016, an estimated 180,890 new cases of prostate cancer were diagnosed and 26,120 deaths related to the disease occurred in the United States. 1 Prostate cancer is one of the most commonly occurring malignancies and is the second leading cause of cancerrelated death among men in the United States. 1, 2 Although the disease is potentially lethal, due in part to widespread screening -which allows for early detection -and advances in treatment, many men with prostate cancer die of other illnesses not related to prostate cancer. [3] [4] [5] The 10-and 15-year survival rates for prostate cancer are 98% and 95%, respectively, and the relative 5-year survival rate is nearly 100%. 1 In general, treatment for prostate cancer involves surgery, radiotherapy, hormone therapy, and chemotherapy. 2 Depending on age, stage of the disease, and other comorbidities, active surveillance may be a more appropriate strategy, especially for older individuals with low-grade and early-stage tumors. 2 Many life-extending treatment options are available to men diagnosed with prostate cancer, so the quality of life (QOL) available to these men following treatment has become a salient concern.
Common QOL challenges that men with prostate cancer often encounter include anxiety, depression, loss of sexual and urinary function, financial burden, loss of social support, and fear of dying. [6] [7] [8] [9] Some men with prostate cancer reported that they were willing to trade off the possibility of living a longer life in return for better QOL. 10 Of interest is whether concerns about QOL may be influenced by issues of medical mistrust. For example, Sheppard et al 11 found that medical mistrust was associated with increased anxiety and depression among black women with breast cancer. It is also known that black men with prostate cancer report higher levels of medical mistrust than white men; however, little is known about the effects of medical mistrust among men with prostate cancer. 12, 13 As a concept, mistrust remains debated among researchers, but the consensus is that trust is a multidimensional construct that can be conceptualized as being both interpersonal and institutional.
14 Interpersonal trust involves trusting other people's behavior and intentions personally or their attributes; by contrast, institutional trust includes the trust a person has in systems of knowledge, groups of people, or institutions. 14, 15 Institutional mistrust is a belief "with feelings of relative certainty or confidence that favorable conditions that are conducive to situational success in a risky endeavor or aspect of one's life are not in place." 15 Mistrust is defined as general lack of trust in the motives of individuals and organizations. 16 Medical mistrust is further defined as distrust of the medical system, health care professionals, and treatments.
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Purpose
The objective of the current study was to examine the association between medical mistrust and overall QOL among black and white men with prostate cancer. Although previous studies have examined medical mistrust, few have examined the influence of medical mistrust in the context of prostate cancer. 12, [17] [18] [19] [20] [21] [22] Level of education, race, prior health care experiences, and cultural factors have all been suggested to be predictors of medical mistrust among men with prostate cancer. 12 However, of the studies that examined medical mistrust in the context of prostate cancer, none explored the effects of medical mistrust on QOL among black or white men with prostate cancer after treatment. Due to the racial disparities that exist among men with prostate cancer across the continuum of care, 13, 23 reduced QOL found among black vs white men with prostate cancer and the consistent racial differences in medical mistrust, 12, 19, 23, 24 examining the association between medical mistrust and overall QOL after stratifying by race is of particular interest.
Methods
The Diagnosis and Decisions in Prostate Cancer Treatment Outcomes trial is a cross-sectional study designed to examine factors that influence the selection of treatment modality for prostate cancer, the racial differences in disease burden, and quality of life. Using a rapid case ascertainment procedure, we retrospectively recruited 877 men (415 black, 462 white) between the ages of 40 to 81 years who entered the North Carolina Central Cancer Registry during the years 2007 and 2008. Eligibility criteria were: men at least 35 years of age, diagnosed and treated for prostate cancer, and self-identified as white or black. Recruitment began in October 2009 and ended in December 2011. On a monthly basis, staff at the North Carolina Central Cancer contacted the primary research network hospitals to request reports identifying patients meeting the eligibility criteria. The North Carolina Central Cancer Registry mailed prospective study participants a pamphlet describing the study and informing them that they may be contacted in the future to participate in a study.
After our study team confirmed eligibility of the patients, the North Carolina Central Cancer Registry mailed the physician of record of each eligible patient a notification of intent to contact the prospective participant about enrolling in the study. Physicians were given 3 weeks to object to our request to contact their patient. If the physician did not refuse patient contact within 3 weeks, the eligible patient was mailed a packet containing a recruitment letter describing the study, a North Carolina Central Cancer Registry brochure, and a copy of the consent forms. In the letter, a phone number was provided so that prospective participants could call for questions or to decline inclusion.
Interviewers contacted the prospective study participant by telephone, screened them for study eligibility, explained the study, answered questions, and sought their participation. If the candidate agreed to participate, then the interviewer reviewed the consent form, obtained verbal consent, and proceeded with the survey questionnaire. The survey consisted of a series of questions related to prostate cancer, the process of care, and their QOL after treatment. The study was approved by the Institutional Review Boards of the Johns Hopkins Bloomberg School of Public Health, the US Department of Defense, and North Carolina Central Cancer Registry.
Measures
Quality of Life
The third version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire was used to measure overall QOL, the dependent variable. The FACT-P is a multidimensional, validated, self-report QOL instrument designed for use in men with prostate cancer. 25 This self-report instrument consists of 34 items on the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire and a 12-item disease-specific subscale for prostate cancer. The FACT-G instrument has 5 subscales covering 4 domains of QOL: physical, social, emotional, and functional well-being. The fifth subscale assesses a respondent's relationship with his physician. Each item is rated on a 0 to 4 Likert-type scale that is then summed to produce the QOL score. Higher scores represent better QOL.
Medical Mistrust
The primary independent variable of the study, medical mistrust, was assessed using the 7-item Medi-cal Mistrust Index, as previously described. 26 Briefly, the scale employs 1 to 4 Likert-type responses ranging from "strongly disagree" to "strongly agree." Examples of items included in the mistrust scale are: "Sometimes I wonder if the hospital's staff members really know what they are doing," "Patients have sometimes been deceived or misled by hospitals," and "When dealing with hospitals, one better be cautious." The mean across all the measures of each respondent has been established to be a reliable score of their trust in the health care system, with higher mean scores reflecting greater levels of medical mistrust. 26 Covariates included demographical and clinical variables. Demographical variables included race (1 = black, 0 = white), age, marital status, level of education, and annual household income (Table 1) . Health insurance coverage was assessed based on participant response to the following item, "Do you have private health insurance, Medicare, Medicaid, Civilian Health and Medical Program of the Uniformed Services (CHAM-PUS) or Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA)?" Those who responded "yes" to having any of the health insurances listed were considered to be insured, and those who did not have any health insurance coverage were considered to be uninsured.
Clinical variables included treatment modality, Gleason score, and time between diagnosis and treatment (see Table 1 ). The amount of time in months that passed between diagnosis and initial treatment was calculated. Respondents were asked, "In what month and year were you diagnosed with prostate cancer?" They were also asked, "In what month and year did you receive your first treatment?" Time between diagnosis and initial treatment was calculated by subtracting the time in months that lapsed between diagnosis and initial treatment for each man. Men who reported their treatment as active surveillance were not included in the time between diagnosis and initial treatment analysis. A categorical time variable was then created (> 3 months, 3-9 months, > 9 months). Gleason scores were obtained from pathology reports and were separated into 3 different categories: low-(≤ 6), medium- (7), and high-grade cancer (8-10).
Data Analysis
We used student t tests for continuous variables and Medical mistrust (mean ± SD) 2.6 ± 0.1 2.7 ± 0.3 2.4 ± 0.4 < .001 GED = general educational development, QOL = quality of life, SD = standard deviation.
chi-square tests for categorical variables to compare select demographical and clinical variables by race. Linear regression models were specified to examine the association between medical mistrust and overall QOL as well as medical mistrust with each of the overall QOL subscales. Estimates of β and corresponding standard error (SE) were used to present findings from the regression models. The model in Table 2 tested the association between medical mistrust and overall QOL among study participants, controlling for age, marital status, education, income, Gleason score, insurance status, treatment received, and time between diagnosis and treatment. The associations between medical mistrust and each of the FACT-P subscale (respondents' relationship with their physician and their physical, social, emotional, and functional well-being) among study participants were examined using linear regression analysis. P values less than .05 were considered to be significant. All calculations and statistical procedures were performed using STATA, v13.1 (StataCorp, College Station, TX).
Results
Black men with prostate cancer tended to be younger, were less likely to be insured, and were less likely to be married compared with white men with prostate cancer (see Table 1 ). Although a higher percentage of black men (34.6%) had a high school or general educational development diploma compared with white men (16.1%), fewer black men (15.9%) had a bachelor's degree compared with white men (29.7%). Significant differences were observed among black and white men with regard to treatment modality; however, prostatectomy was the most common treatment among both black (63.9%) and white (71.5%) men. No differences were observed among black and white men with regard to the grade of prostate cancer, as indicated by Gleason scores (see Table 1 ). Black men with prostate cancer reported a higher level of medical mistrust (black = 2.7, white = 2.4; P < .001) and a lower overall QOL (black = 134.4, white = 139.5; P < .001).
The regression model found in Table 2 was designed to examine the association between medical mistrust and overall QOL among men with prostate cancer. Higher levels of medical mistrust were associated with reduced overall QOL among study participants after controlling for age, marital status, education, income, Gleason score, insurance coverage status, treatment received, and time between diagnosis and treatment (β = -7.73; SE 1.54). The associations between medical mistrust and each of the overall QOL subscales (respondents' relationship with their physician and their physical, social, emotional, and functional well-being) were also examined. After controlling for age, marital status, education, income, Gleason score, health insurance coverage status, treatment received, and time between diagnosis and treatment, higher levels of medical mistrust among study participants were associated with overall lower QOL levels of social well-being (β = -1.13; SE 0.35), functional well-being (β = -2.20; SE 0.43), emotional well-being (β = -0.63; SE 0.19) and diminished relationship with their physicians (β = -0.47; SE 0.11).
Discussion
This study provides evidence that demonstrates the association between medical mistrust and overall QOL among black and white men diagnosed with and treated for prostate cancer. After controlling for demographical and clinical variables, high levels of medical mistrust were associated with low levels in overall QOL among men with prostate cancer. These findings point to a previously unidentified opportunity -linked to increasing patient trust in the medical system -that health care professionals can explore in the hopes of enhancing QOL among patients with prostate cancer. With the incidence of prostate cancer diagnoses increasing, and with men living longer lives after being diagnosed with prostate cancer, it is imperative that health care professionals and researchers also focus on managing issues of QOL among this patient population.
Results from the current study and others have suggested that black men with prostate cancer are more likely to report higher levels of medical mistrust than white men. 12, 13 These findings may be important because previous work has demonstrated that medical mistrust is not significantly associated with failure to receive needed medical care; however, medical mistrust can serve as a barrier to optimal health. 26 Higher levels of medical mistrust have been found to be associated with failure to take medical advice, failure to keep follow-up appointments, and postponement of receiving needed care. 26 With excellent survival rates following treatment for prostate cancer, 1 it is imperative that patients and their health care professionals discuss post-treatment QOL issues throughout the continuum of care and work in unison to address possible issues with medical mistrust. As the data in the current study suggest, optimal post-treatment QOL for certain men with prostate cancer could be hindered as a result of medical mistrust.
Limitations
Some limitations are associated with this study. Because this study was cross-sectional and initially commissioned to explore treatment modality, racial differences in disease burden, and QOL issues after diagnosis and treatment, data were not obtained on the level of medical mistrust among these men prior to their diagnosis and treatment of prostate cancer. As a result, no determination can be made on whether the level of medical mistrust led to a reduction in QOL or whether a reduction in QOL led to an elevated level of medical mistrust.
Strengths
Several strengths are associated with this research. Although previously published data identified higher levels of medical mistrust among black men with prostate cancer, the results of the current study add insight into how medical mistrust can affect both black and white men with prostate cancer. 12 This study also made use of validated measures and a large sample size. Doing so allowed us to incorporate the data of men who underwent diverse treatment procedures and men whose grade of disease ranged from low-to high-grade cancer, thereby enhancing the generalizability of our findings.
Conclusions
Some men with prostate cancer previously reported that they were willing to trade off the possibility of living a longer life in return for better quality of life (QOL). 10 Interventions targeted to reduce medical mistrust may be an effective method in enhancing the QOL of men with prostate cancer. The results of this study indicate that higher levels of medical mistrust among men with prostate cancer are associated with lower overall QOL. Future research on the level of medical mistrust among patients with prostate cancer should focus on the consequences of medical mistrust among this patient population. The findings of the current study should also serve as the impetus for future research on medical mistrust among men with prostate cancer with the goal of improving QOL.
